[Funding alert] PlasmaGen Biosciences Secures Rs 225 Cr Equity Investment

High-net-worth individuals (HNIs) such as Ashish Rameshchandra Kacholia and Artian Investments, a UK-based investment banking firm, invested equity finance of around Rs 225 crore (nearly $27 million) to the biopharmaceutical startup PlasmaGen Biosciences.

F-Prime Capital, an existing shareholder, and Eight Roads Ventures, an early backer, also took part in the fundraising.

Read also – [Funding alert] Quantum-Safe Data Security Platform QNu Labs Secures $6.5 Mn Pre-Series A1 Funding

The business from Bengaluru would utilise the money to accelerate the growth of its plasma goods. Additionally, it is anticipated that the corpus would be used to develop goods, finance working capital needs, and increase its global footprint.

“This latest funding strengthens our position in our mission to be a trusted and leading Indian biopharmaceutical company, dedicated towards improving the health and quality of life of patients. We’re grateful to all our investors for their partnership as we continue to improve the accessibility of blood-plasma derived products for patients in India and emerging countries,” said Vinod Nahar, founder and managing director, PlasmaGen Biosciences.

Read also – [Funding alert] EV Charging Startup Exponent Energy Secures $26 Mn Funding Led by Eight Roads Ventures

Since 2010, PlasmaGen has been running its business with the primary goal of linking the nation’s supply and demand for plasma protein products, ultimately enhancing the health and standard of living for thousands of people.

About PlasmaGen Biosciences

The first company in India dedicated to plasma protein therapeutics, PlasmaGen BioSciences Private Limited was founded in Bengaluru in 2010.

Read also – Subeer Bakshi of PhonePe Joins Pocket FM as People and Culture Head

With a focus on and depth of knowledge in the field of plasma product therapies, PlasmaGen BioSciences collaborates closely with government organisations to solve a range of concerns, including cost, accessibility, and hemovigilance. We intend to expand and utilise this commitment to facilitate the expansion of Plasma Protein Therapy throughout SAARC countries and other developing economies.